en · de · es · pt
tb-500-notes.peptides6088.com › Faq › Tb-500 Identity And Molecular Background — What the Evidence Shows

Tb-500 Identity And Molecular Background — What the Evidence Shows

By Editorial Desk · published 2026-04-28 · last reviewed 2026-05-22 · Faq

thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Calculated for the acetylated heptapeptide
Molecular weight~889 DaMonoisotopic mass approximately 889.0 Da
Amino acid sequenceAc-LKKTETQN-terminal acetylated seven-residue peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classWater-solublePeptides of this size generally dissolve in aqueous media

Thymosin Beta-4 Fragment Overview

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

Related pages on this site

Identity and Physical Form

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Further detail

== Companies == Contaminated products found in the China AQSIS tests include baby formula products produced by the following companies, in order of highest concentration found. Shijiazhuang Sanlu Group, Shanghai Panda Dairy, Qingdao Shengyuan Dairy, Shanxi Gu Cheng Dairy, Jiangxi Guangming Yingxiong Dairy, Baoji Huimin Dairy, Inner Mongolia Mengniu Dairy, Torador Dairy Industry (Tianjin), Guangdong Yashili Group, Hunan Peiyi Dairy, Heilongjiang Qilin Dairy, Shanxi Yashili Dairy, Shenzhen Jinbishi Milk, Scient (Guangzhou) Infant Nutrition, Guangzhou Jinding Dairy Products Factory, Inner Mongolia Yili Industrial Group, Yantai Ausmeadow Nutriment, Qingdao Suncare Nutritional Technology, Xi'an Baiyue Dairy, Yantai Leilei Dairy, Shanghai Baoanli Dairy, and Fuding Chenguan Dairy.

=== Reversing the mechanism === The antioxidant N-acetyl-L-cysteine (NAC) is known to significantly reduce the cytotoxicity induced by DCBQ. NAC is a precursor of sulfhydryl-containing tripeptide glutathione (GSH), which is produced and kept at high levels in all cells, helping them defend against oxidative stress. Once NAC is inside the cell, it is rapidly hydrolyzed to cysteine so that it can be used to form GSH. Restoring the high GSH levels in the cell. NAC is available in oral, inhalation, and intravenous (IV) formulations.

=== Yeast amino acid metabolism === In 1912 Felix Ehrlich demonstrated that yeast metabolizes the natural amino acids essentially by splitting off carbon dioxide and replacing the amino group with a hydroxyl group. By this reaction, tryptophan gives rise to tryptophol.

=== Haymarket grows === From the autumn of 1964, Haymarket set out aggressively to acquire magazines, approaching them from the list in the media directory BRAD. They acquired small, modestly profitable magazines for tape recorder and camera, and camping and caravan, enthusiasts, and using a loan from BPC bought a series of leisure and medical publications for £250,000 from a Canadian publisher, in competition with Thomson Group. In 1965 Heseltine's businesses had a turnover of around £700,000 per annum, and employed around 50 staff. Although the Opportunities for Graduates series continued to generate profits, Town magazine continued to lose money, hampered by the cost of printing (much more expensive at that time than nowadays) and by Heseltine's reluctance, for political reasons, to include pictures of nude girls or cartoons disrespectful of the Royal Family. Haymarket launched a bid for the British Institute of Management's magazine The Manager, again in competition with Thomson Group, in late 1965. It was envisaged that Haymarket would take a 25% stake, as would the Financial Times and The Economist, of both of which Crowther was also chairman. Over the weekend Heseltine, inspired by how Donald Stokes had once won a Scandinavian bus contract for British Leyland by building a model bus, had a team led by Labovitch prepare a 96-page mock copy of what they envisaged, mostly using text cut from The Economist.

The term supermolecule (or supramolecule) was introduced by Karl Lothar Wolf et al. (Übermoleküle) in 1937 to describe hydrogen-bonded acetic acid dimers. The term supermolecule is also used in biochemistry to describe complexes of biomolecules, such as peptides and oligonucleotides composed of multiple strands. Eventually, chemists applied these concepts to synthetic systems. One breakthrough came in the 1960s with the synthesis of the crown ethers by Charles J. Pedersen. Following this work, other researchers such as Donald J. Cram, Jean-Marie Lehn and Fritz Vögtle reported a variety of three-dimensional receptors, and throughout the 1980s research in the area gathered a rapid pace with concepts such as mechanically interlocked molecular architectures emerging. The influence of supramolecular chemistry was established by the 1987 Nobel Prize for Chemistry which was awarded to Donald J. Cram, Jean-Marie Lehn, and Charles J. Pedersen in recognition of their work in this area. The development of selective "host–guest" complexes in particular, in which a host molecule recognizes and selectively binds a certain guest, was cited as an important contribution.

Sources: en.wikipedia.org

Background from the literature

Ronald Dickson Woodroof (February 3, 1950 – September 12, 1992) was an American man who created what would become known as the Dallas Buyers Club in March 1988, one of several such AIDS buyers clubs that sprang up at the time. After learning he had contracted the human immunodeficiency virus (HIV) in 1985 and being diagnosed with AIDS, he created the group as part of his efforts to find and distribute drugs to treat AIDS at a time when the disease was poorly understood. He sued the United States Food and Drug Administration (FDA) over a ban on peptide T, a drug he was using. Woodroof's final years became the basis of the 2013 film Dallas Buyers Club, in which he was portrayed by Matthew McConaughey.

=== Soviet Union === One result of the Tehran Conference in November 1943 was an invitation for an Anglo-American scientific mission to visit the Soviet Union. The British team consisted of Florey and Sanders; the American of Albert Baird Hastings and Michael Boris Shimkin. After a month's travel via North Africa and Iran, they reached Moscow on 23 January 1944, where they met Soviet microbiologist Zinaida Yermolyeva. Florey gave her samples of penicillin, and she gave him a sample of the antibiotic Gramicidin S. He arrived back at Oxford on 29 March 1944.

Originally, seven such proteins were discovered. Of these, six (BMP2 through BMP7) belong to the Transforming growth factor beta superfamily of proteins. BMP1 is a metalloprotease. Since then, thirteen more BMPs, all of which are in the TGF-beta family, have been discovered, bringing the total to twenty. The current nomenclature only recognizes 13, as many others are put under the growth differentiation factor naming instead.

The fission of one atom of uranium-235 releases 202.5 MeV (3.24×10−11 J) inside the reactor. That corresponds to 19.54 TJ/mol, or 83.14 TJ/kg. Another 8.8 MeV escapes the reactor as anti-neutrinos. When 23592U nuclei are bombarded with neutrons, one of the many fission reactions that it can undergo is the following (shown in the adjacent image):

Sources: en.wikipedia.org

Reference notes

In March 2009, Komsomolskaya Pravda reported that on the morning of 8 August 2008, at around 6:00 AM tank shell hit the observer post and wounded lieutenant Oleg Galavanov. Galavanov had returned from Russia to Tskhinvali in 2007 and worked in the Ministry of Defense and Emergency Situations of South Ossetia. He served as artillery spotter. In August 2009, South Ossetian news agency RES reported that 32-year old Oleg Galavanov had been promoted to the rank of lieutenant in 2007. In October 2008, Konstantin Timerman, the commander of the Russian peacekeeping battalion, said in an interview with Izvestia that on the morning of 8 August the Russians opened fire in response only after the Georgians had opened fire on the observer post in the southern part of Tskhinvali. If we take into consideration that Golovanov is listed as an employee of the South Ossetian Defense Ministry, it turns out that the Georgian fire against the Russian peacekeeping base was provoked by the Ossetian fire from the roof. In 2009, the Russian authorities told the Tagliavini commission that the Russian peacekeepers suffered the first casualties at 6:35 am on 8 August, when the Georgian tank was firing on the observer post on the roof of the peacekeepers' base. As a result one soldier of the battalion died, another one was wounded and the part of the building was destroyed. By noon two peacekeepers had died and five were wounded. Georgia said that it only targeted Russian peacekeepers in self-defence, after coming under fire from them.

==== Orthopedics ==== As of 2017, use of mesenchymal stem cells (MSCs) derived from adult stem cells was under preliminary research for potential orthopedic applications in bone and muscle trauma, cartilage repair, osteoarthritis, intervertebral disc surgery, rotator cuff surgery, and musculoskeletal disorders, among others. Other areas of orthopedic research for uses of MSCs include tissue engineering and regenerative medicine.

Vacuum is useful in a variety of processes and devices. Its first widespread use was in the incandescent light bulb to protect the filament from chemical degradation. The chemical inertness produced by a vacuum is also useful for electron-beam welding, cold welding, vacuum packing and vacuum frying. Ultra-high vacuum is used in the study of atomically clean substrates, as only a very good vacuum preserves atomic-scale clean surfaces for a reasonably long time (on the order of minutes to days). High to ultra-high vacuum removes the obstruction of air, allowing particle beams to deposit or remove materials without contamination. This is the principle behind chemical vapor deposition, physical vapor deposition, and dry etching which are essential to the fabrication of semiconductors and optical coatings, and to surface science. The reduction of convection provides the thermal insulation of thermos bottles. Deep vacuum lowers the boiling point of liquids and promotes low temperature outgassing which is used in freeze drying, adhesive preparation, distillation, metallurgy, and process purging. The electrical properties of vacuum make electron microscopes and vacuum tubes possible, including cathode-ray tubes. Vacuum interrupters are used in electrical switchgear. Vacuum arc processes are industrially important for production of certain grades of steel or high purity materials. The elimination of air friction is useful for flywheel energy storage and ultracentrifuges.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.

How does TB-500 appear in the literature?

It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

Network